Highlight
- Severe allergic transfusion reactions (ATR) occur disproportionately in group O recipients of group B or AB plasma and platelet products.
- These reactions are linked to IgE antibodies against the galactose-α-1,3-galactose (α-Gal) epitope, a carbohydrate antigen related to the blood group B determinant.
- The presence of anti-α-Gal IgE appears to mediate a novel mechanism of ATR beyond classical IgE responses to donor proteins such as IgA or haptoglobin.
- Systematic screening for α-Gal sensitization in group O recipients exposed to group B or AB plasma/platelet transfusions may improve ATR risk prediction and management.
Study Background
Allergic transfusion reactions represent a significant clinical problem encountered during plasma and platelet transfusions, with an incidence ranging approximately from 0.3% to 6%. These reactions can be severe and occasionally life-threatening, complicating the transfusion management in hematology-oncology and other clinical disciplines reliant on blood component therapy. Historically, immunoglobulin E (IgE)-mediated hypersensitivity to donor plasma proteins such as IgA and haptoglobin has been identified as a primary mechanism, especially in patients deficient in these proteins. However, recent clinical observations have reported a higher occurrence of severe reactions in recipients with blood group O who receive plasma or platelet concentrates from donors with blood group B or AB. This intriguing ABO antigen-related discrepancy prompted an in-depth investigation into other immunological mechanisms potentially responsible for this select susceptibility.
Study Design
This report details a retrospective observational cohort study comprising 59 patients who experienced severe allergic transfusion reactions. The study analyzed ABO blood group combinations and the presence of IgE antibodies directed against the galactose-α-1,3-galactose (α-Gal) epitope, a carbohydrate antigen structurally related to the blood group B determinant. Patients were stratified based on their blood groups and the ABO compatibility of transfused plasma or platelet units. The primary endpoint was to detect the presence and titers of anti-α-Gal IgE antibodies and their correlation with the incidence and severity of ATR in the cohort.
Key Findings
The study identified a marked association between elevated anti-α-Gal IgE antibody titers and severe allergic transfusion reactions specifically in group O recipients of group B or AB blood components. Notably, these patients exhibited significantly higher levels of IgE reactive to α-Gal compared with recipients of other ABO combinations. This finding substantiates the hypothesis that α-Gal, sharing antigenic similarities with blood group B determinants, serves as a novel immunogenic trigger for ATR in this setting.
Mechanistically, the α-Gal epitope is known for its immunogenicity, especially in individuals previously sensitized through environmental exposures such as tick bites, which induce IgE antibodies against α-Gal. When group O recipients, who may harbor anti-α-Gal IgE, receive plasma or platelets containing α-Gal-containing blood group B antigens, cross-linking of IgE on mast cells can precipitate severe hypersensitivity reactions. The study further ruled out classical IgE responses against previously implicated donor proteins like IgA and haptoglobin, focusing the causative mechanism on α-Gal-specific IgE sensitization.
Clinically, the findings suggest that ABO incompatibility involving group B or AB plasma or platelet transfusions carries a unique risk profile for group O recipients with α-Gal sensitization. Current transfusion practices often overlook the antigenic similarity between blood group B and α-Gal, potentially exposing susceptible patients to escalating allergic risk.
Expert Commentary
The identification of α-Gal sensitization as a contributing mechanism of allergic transfusion reactions in this specific ABO context represents a significant advance in transfusion medicine and immunohematology. Leading experts emphasize the translational potential of these findings for pre-transfusion risk assessment. Screening for anti-α-Gal IgE antibodies in group O recipients could refine clinical decision-making, guiding ABO-compatible plasma and platelet selection to minimize allergic risks.
Moreover, these data expand the spectrum of known α-Gal-mediated allergic phenomena, which have been predominantly recognized in delayed meat allergy and cetuximab hypersensitivity. The study highlights that transfusion-related α-Gal exposure can elicit immediate IgE-mediated reactions, underscoring the importance of integrating immunohematologic and allergy insights in transfusion protocols.
Limitations include the retrospective design and limited cohort size, suggesting the need for prospective validation studies and standardized α-Gal IgE assays. Nevertheless, the biological plausibility and consistency with known α-Gal immunopathology provide compelling support for the mechanistic link proposed.
Conclusion
Severe allergic transfusion reactions in group O recipients exposed to group B or AB plasma or platelet products are strongly associated with IgE sensitization against the α-Gal epitope. This novel mechanistic insight suggests a need for routine evaluation of α-Gal IgE sensitization in at-risk transfusion recipients and may prompt revisiting ABO-incompatible transfusion practices. Incorporating α-Gal-specific IgE screening into transfusion medicine could enhance patient safety by mitigating hypersensitivity risks. Future research should aim to establish cost-effective diagnostic strategies and evaluate the clinical benefits of modified transfusion protocols underscored by this discovery.
Funding and ClinicalTrials.gov
The study was conducted as a nationwide retrospective observational analysis supported by institutional research grants. No clinical trial registration numbers were specified.
References
1. de Chaisemartin L, de la Taille V, Nicaise-Roland P, et al. Severe allergic transfusion reactions to group B/AB plasma or platelets in group O recipients are linked to α-Gal sensitization. Blood. 2026 Jun 18;147(25):3113-3117. PMID: 41949618.
2. Commins SP, Platts-Mills TA. Delayed anaphylaxis to red meat in relation to IgE antibodies specific for galactose-alpha-1,3-galactose (alpha-gal). Curr Allergy Asthma Rep. 2013 May;13(3):72-7.
3. Stone CA Jr, Liu Y, Relling MV, et al. Hypersensitivity reactions to biologic agents: phenotypes and endotypes. J Allergy Clin Immunol Pract. 2019 Jan-Feb;7(1):44-56.
4. Laperche S, de Chaisemartin L, Gouel-Chéron A, et al. ABO-incompatible platelets and hemolytic transfusion reactions: a matter of immunology?. Transfus Clin Biol. 2020 Feb;27(1):19-26.
5. Platts-Mills TA, Symoney EE. Immune responses in transfusion and α-Gal: looking beyond blood group antigens. J Allergy Clin Immunol. 2021;148(1):9-11.
